Insilico Medicine to Present First-in-Human Data on AI-Designed IBD Candidate at DDW 2026
TipRanks
Last updated: May 2, 2026
Insilico Medicine has announced a planned clinical data presentation for Garutadustat (formerly ISM5411) at Digestive Disease Week 2026. This presentation will focus on the drug's development and potential applications, particularly in the context of chronic kidney disease (CKD) and anemia.
- Insilico Medicine is preparing to present clinical data for Garutadustat, a novel small molecule inhibitor of HIF-PHD, at Digestive Disease Week 2026 in Chicago.
- This drug candidate is being investigated for its efficacy in treating anemia associated with chronic kidney disease (CKD).
- The company's previous research and development efforts have focused on advancing Garutadustat through clinical trials.
- The presentation at Digestive Disease Week signifies a step in sharing progress and potentially engaging with the medical community regarding this therapeutic.
- The specific details of the data to be presented were not fully disclosed in the initial announcement, but the event itself serves as a platform for scientific exchange.
- Insilico Medicine's work on Garutadustat is part of its broader strategy to develop innovative treatments for various diseases.
- The inclusion of this presentation at a prominent gastroenterology and hepatology conference suggests potential implications for gastrointestinal health in CKD patients.
- Further information is expected to be revealed at the conference regarding Garutadustat's clinical profile and its position within the treatment landscape for CKD-related anemia.
